论文部分内容阅读
目的探讨瑞格列奈与二甲双胍治疗继发性失效糖尿病的疗效。方法 196例继发性失效糖尿病患者随机分为观察组与治疗组,分别采用口服瑞格列奈和二甲双胍治疗,1月后观察空腹血糖、餐后2 h血糖及HbA1c。结果两组空腹、餐后2 h血糖、HbA1c都有明显下降,观察组治疗后空腹、餐后2 h血糖、HbA1c均明显低于对照组,差异有统计学意义(P<0.05)。观察组轻度低血糖发生共2例次(2.04%),患者均自行纠正;对照组发生不良反应共10例次(10.20%),其中6例出现恶心、上腹部不适,4例有腹胀、轻度腹泻,对症治疗后可耐受而继续服用二甲双胍按疗程治疗。观察组不良反应发生率明显低于对照组,差异有统计学意义(χ2=5.68,P<0.05)。结论瑞格列奈治疗SFS糖尿病患者临床疗效好,不良反应少,是SFS糖尿病患者的理想选择。
Objective To investigate the efficacy of repaglinide and metformin in the treatment of secondary failure of diabetes mellitus. Methods One hundred and sixty-six patients with secondary failure of diabetes were randomly divided into observation group and treatment group. The patients were treated with oral repaglinide and metformin respectively. After one month, the fasting blood glucose, postprandial blood glucose and HbA1c were observed. Results Both fasting and postprandial blood glucose and HbA1c were significantly decreased in both groups. The fasting and postprandial blood glucose and HbA1c in the observation group were significantly lower than those in the control group (P <0.05). In the observation group, mild hypoglycemia occurred in 2 cases (2.04%). All the patients were corrected by themselves. There were 10 cases (10.20%) of the adverse reactions in the control group, including nausea and discomfort in 6 cases, abdominal distension in 4 cases, Mild diarrhea, symptomatic treatment may be tolerated and continue to take metformin by treatment. The incidence of adverse reactions in the observation group was significantly lower than that in the control group (χ2 = 5.68, P <0.05). Conclusion Repaglinide is an ideal choice for patients with SFS due to its good clinical efficacy and few adverse reactions.